ClinicalTrials.gg
RecruitingNCT05770349MITOCH-HFUpdated Oct 6, 2026

Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure

An observational study in Heart Failure and Coronary Artery Disease, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.

Planned enrollment
10th of 10
45 · median 250
Started
2023
with 5 others
Observational
10 of 25
6 open now
Registered
14th of 25
by date
Lead sponsor
4 of 25
Tomsk National Research Medical Center of the Russian Academy of Sciences

Among the 25 studies in Heart Failure with a site in Russia, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 6 that started in 2023, is one of 10 observational ones, and was the 14th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Failure with a site in Russia, or all of them as a file.
02

Study summary

According to modern concepts, mitochondrial dysfunction may be the fundamental basis for the development and progression of CHF, including in patients undergoing myocardial revascularization. The processes of mitochondrial fusion, division and mitophagy are aimed at maintaining cellular homeostasis. A change in the balance of these processes can lead to the accumulation of damaged organelles with impaired functions. In patients with CHF, dysfunctional mitochondria are characterized by size dispersion, crist disorganization, and localization changes relative to myofibrils.

At the same time, the topic of the influence of mitochondrial dysfunction on the prognosis and clinical course of CHF remains debatable today. Direct study of the structural and functional features of mitochondria in human cardiomyocytes is an extremely difficult task, and therefore, such studies are carried out extremely rarely and on very limited cohorts. In the planned study, due to the long time of the study material recruitment, the ultrastructure of mitochondria in a large cohort of patients, ranging from 45 to 60 people, will be studied.

The aim of this study is to study the association of mitochondrial dysfunction with the clinical course and outcomes of CHF of ischemic etiology, as well as to assess the degree of compliance of indirect criteria of mitochondrial dysfunction with direct ultrastructural characteristics of mitochondria in cardiomyocytes.

This single-center prospective cohort study will involve 45-60 patients. The patients will have biopsy samples taken from the right auricle, as well as blood collection and preservation and its derivatives. Electron microscopy of myocardial samples will be performed to assess the ultrastructure of mitochondria of cardiomyocytes. The results of a direct study of mitochondria will be compared with indirect signs of mitochondrial dysfunction: the registration of the phenomenon of increased leaching of radiopharmaceuticals from the myocardium, an increase in the number of copies of mitochondrial DNA and the concentration of cytochrome C in the blood, the affiliation of mitochondrial DNA to haplogroup K. The results obtained in each of the research tasks will have high scientific significance and publication potential.

Read the detailed description

According to modern concepts, mitochondrial dysfunction may be the fundamental basis for the development and progression of CHF, including in patients undergoing myocardial revascularization. The processes of mitochondrial fusion, division and mitophagy are aimed at maintaining cellular homeostasis. A change in the balance of these processes can lead to the accumulation of damaged organelles with impaired functions. In patients with CHF, dysfunctional mitochondria are characterized by size dispersion, crist disorganization, and localization changes relative to myofibrils.

At the same time, the topic of the influence of mitochondrial dysfunction on the prognosis and clinical course of CHF remains debatable today. Direct study of the structural and functional features of mitochondria in human cardiomyocytes is an extremely difficult task, and therefore, such studies are carried out extremely rarely and on very limited cohorts. In the planned study, due to the long time of the study material recruitment, the ultrastructure of mitochondria in a large cohort of patients, ranging from 45 to 60 people, will be studied.

The aim of this study is to study the association of mitochondrial dysfunction with the clinical course and outcomes of CHF of ischemic etiology, as well as to assess the degree of compliance of indirect criteria of mitochondrial dysfunction with direct ultrastructural characteristics of mitochondria in cardiomyocytes.

This single-center prospective cohort study will involve 45-60 patients. The patients will have biopsy samples taken from the right auricle, as well as blood collection and preservation and its derivatives. Electron microscopy of myocardial samples will be performed to assess the ultrastructure of mitochondria of cardiomyocytes. The results of a direct study of mitochondria will be compared with indirect signs of mitochondrial dysfunction: the registration of the phenomenon of increased leaching of radiopharmaceuticals from the myocardium, an increase in the number of copies of mitochondrial DNA and the concentration of cytochrome C in the blood, the affiliation of mitochondrial DNA to haplogroup K. The results obtained in each of the research tasks will have high scientific significance and publication potential.

The results of the study will be obtained by solving the following tasks:

  1. To investigate the clinical and prognostic significance of mitochondrial dysfunction, confirmed by direct and indirect methods of investigation, in patients with CHF with stenosing atherosclerosis of the coronary arteries who underwent surgical myocardial revascularization in the prospective cohort study;
  2. To study ultrastructural characteristics of mitochondria of cardiomyocytes from the auricle of the right atrium using a transmission electron microscope JEM-1400 (JEOL, Japan) in patients with CHF with reduced or mildly reduced left ventricular ejection fraction (HFrEF, HFmrEF) and stenosing atherosclerosis of the coronary arteries;
  3. To evaluate the features of the mitochondrial genome, in particular, to determine whether the mitochondrial DNA belongs to haplogroup K, which may be associated with impaired adaptation to hypoxia due to the negative effect of guanine replacement on adenine at position 9055 (G9055A) [Strauss K.A. et al. Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3453-8. doi: 10.1073/pnas.1300690110] and its relation to the prognosis of the disease and the ultrastructure of mitochondria according to electron microscopy;
  4. To study the association of the number of copies of mitochondrial DNA in blood plasma with ultrastructural signs of mitochondrial dysfunction in CMC;
  5. To evaluate the content of the biochemical marker of mitochondrial damage - cytochrome C in the blood serum of patients with CHF and to identify the correlation of its concentration with the severity of structural and functional changes in mitochondria;
  6. To assess the significance of the phenomenon of enhanced leaching of the radiopharmaceutical Tc99-MIBI from the myocardium and to determine the degree of correlation of the rate of leaching of Tc99-MIBI with the ultrastructural state of mitochondria, as well as with the clinical course and prognosis of CHF;
  7. Calculate statistical parameters (sensitivity, specificity, degree of concordance) for each of the indirect signs of mitochondrial dysfunction and their totality in the diagnosis of mitochondrial ultrastructure disorders according to electron microscopy data and prediction of the clinical course and outcomes of CHF in patients undergoing surgical myocardial revascularization.

Thus, it is planned to prove for the first time in the world the association of direct ultrastructural signs of mitochondrial dysfunction with the clinical course and outcomes of CHF in patients who underwent surgical myocardial revascularization. For the first time in the world, the degree of compliance of available indirect signs of mitochondrial dysfunction with the true ultrastructural state of mitochondria will be presented, with the inclusion of 45-60 patients in the study. Based on the results of the study, a parameter or a set of parameters will be proposed that will be most associated with the clinical course of the disease and the outcome in patients with CHF of ischemic etiology.

The results obtained will have high world-class scientific significance and importance, both for fundamental medical science and for the practical implementation of the results.

03

Conditions studied

  • Heart Failure
  • Coronary Artery Disease

Keywords

  • Chronic heart failure
  • Mitochondrial function
  • Mitochondrial DNA
  • Electron microscopy
  • SPECT
  • Cytochrome C
  • CABG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

45-60 patients will be included in the study (15-20 people each - in 2023, 2024 and 2025) who meet the stated inclusion and exclusion criteria. The signing of the informed consent will be carried out before the start of any research procedures, the patient will be explained in detail the protocol of the study and the scope of the diagnostic procedures carried out

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The presence of HFrEF or HFmrEF (EF of LV \<50%)
  2. Obstructive multivessel coronary atherosclerosis as an indication for cardiac surgical correction of coronary blood flow (coronary bypass surgery)
  3. Signed to participate in the study, separate consents for biomaterial sampling and genetic research

Exclusion criteria

Exclusion Criteria:

  1. Refusal of revascularization or participation in the study
  2. Additional cardiac surgery other than coronary bypass surgery (valves, aneurysm)
  3. Oncological diseases in the active stage;
  4. The presence of implanted devices (EX, AICD, CT);
  5. Severe renal dysfunction ( \<30 ml/min/1.73 m2);
  6. Infiltrative heart diseases (sarcoidosis, amyloidosis, accumulation diseases);
  7. diseases;
  8. Acute infectious and exacerbations of chronic somatic diseases
  9. Type 1 or type 2 diabetes mellitus
  10. to myocardial scintigraphy, cardiopulmonary stress test
  11. Impossibility of prescribing optimal drug therapy after cardiac surgery
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Procedurecoronary artery bypass grafting

    Coronary artery bypass grafting

06

What researchers measure

Primary outcomes

  1. Combined primary endpoint (percentage)

    Combined primary endpoint is calculated as a percentage (%) of patients with one or several outcomes including: cardiovascular death and/or hospitalization for decompensated HF or the need for parenteral administration of a diuretic and/or acute ischemic events or repeated unplanned revascularization and/or unplanned impalement of cardiac implantable electronic devices.

    Time frame: 12 months

Secondary outcomes

  1. Hospital stay (days)

    Number of days of hospitalization following coronary artery bypass grafting (CABG) surgery.

    Time frame: 30 days

  2. Postoperative complications during hospitalization (percentage)

    Postoperative complications during hospitalization are assessed as percentage of patients with complications after CABG.

    Time frame: 30 days

  3. Incidence of patients with HF worsening (percentage)

    Worsening of heart failure (HF) is assessed based on NYHA class change.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Garganeeva A.A., Kuzheleva E.A., Tukish O.V., Vitt K.N., Andreev S.L., Muslimova E.F., Korepanov V.A., Afanasiev S.A., Gulya M.O., Syromyatnikova E.E., Vladimirova E.A., Stepanov I.V. Possibilities of diagnosis of mitochondrial dysfunction in chronic heart failure. Siberian Journal of Clinical and Experimental Medicine. 2024;39(3):51-57. https://doi.org/10.29001/2073-8552- 2024-39-3-51-57.
  • Muslimova E.F., Kuzheleva E.A., Garganeeva A.A., Afanasiev S.A. Association of mitochondrial DNA C7028T, G3010A, G9055A polymorphisms and the severity of chronic heart failure of ischemic genesis. Siberian Journal of Clinical and Experimental Medicine. 2025;40(4):123-130. https://doi.org/10.29001/2073-8552-2025-40-4-123-130
  • Garganeeva AA, Korepanov VA, Kuzheleva EA, Tukish OV, Vitt KN, Muslimova EF, Afanasiev SA. Chronic heart failure with reduced and mildly reduced left ventricle ejection fraction: relationship between mitochondrial respiratory dysfunction of peripheral blood mononuclear cells and iron deficiency. J Geriatr Cardiol. 2025 Sep 28;22(9):812-817. doi: 10.26599/1671-5411.2025.09.004. PubMed 41143166 ↗
  • Garganeeva AA, Kuzheleva EA, Kazakov EP, Syromyatnikova EE, Tukish OV, Kireev II. Association of Cardiomyocyte Mitochondrial Ultrastructure Features with the Severity of Clinical Manifestations in Heart Failure. Kardiologiia. 2026 Jan 14;65(12):13-19. doi: 10.18087/cardio.2025.12.n3062. English, Russian. PubMed 41531353 ↗
  • Kuzheleva EA, Garganeeva AA, Tukish OV, Vitt KN, Andreev SL, Syromyatnikova EE, Vladimirova EA. Total Area of Interfibrillar Mitochondria in the Right Atrial Appendage Cardiomyocytes as an Index of the Functional State of the Cardiovascular System in Chronic Heart Failure. Bull Exp Biol Med. 2025 Feb;178(4):486-490. doi: 10.1007/s10517-025-06361-7. Epub 2025 Mar 26. PubMed 40138111 ↗
  • Garganeeva A.A., Tukish O.V., Kuzheleva E.A., Gulya M.O., Muslimova E.F., Zhargasova V.A., Popov S.V. Heart failure and mitochondrial dysfunction: research methods in experiment and clinical practice. Acta biomedica scientifica. 2025; 10(1): 103-114. doi: 10.29413/ABS.2025-10.1.11
  • Garganeeva AA, Kuzheleva EA, Tukish OV, Vitt KN, Kondratiev MY, Syromyatnikova EE, Andreev SL, Arsenieva YA, Korepanov VA, Afanasiev SA. Acute Decompensated Heart Failure: Structural and Functional Changes in Mitochondria. Kardiologiia. 2024 Dec 24;64(12):12-18. doi: 10.18087/cardio.2024.12.n2737. English, Russian. PubMed 39784128 ↗
  • Liao M, Men L, Gong M, Li Y, Wang Y, Xu D, Luan J, Zhou H, Liu M, Chen M. Mitophagy: a novel avenue for herbal medicines alleviating myocardial ischemia/reperfusion injury. Apoptosis. 2025 Dec;30(11-12):2676-2693. doi: 10.1007/s10495-025-02178-x. Epub 2025 Sep 12. PubMed 40938522 ↗

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2026, 44 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 44 months is close to that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 15, 2023
StartActual
Mar 31, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05770349
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborators
Russian Science Foundation
Responsible party
Elena A. Kuzheleva (Senior Researcher, Tomsk National Research Medical Center of the Russian Academy of Sciences) — Principal investigator
First posted
Mar 15, 2023
Start date
Mar 31, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Elena A Kuzheleva, Ph.D.
Contact
kea@cardio-tomsk.ru
+79234010502
Olga V Tukish, Ph.D.
Contact
olgatukish@yandex.ru
+79069476343
Alla A Garganeeva, Ph.D.
principal investigator · Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion